Stay updated on Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A new Locations section appears with Texas as a study site. The previous Texas Locations entry and the HHS Vulnerability Disclosure link were removed; the page revision updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T17:25:23.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The study results status changed from No Results Posted to Results Submitted, indicating that the trial results are now being prepared for posting. This affects the availability of outcome information for stakeholders reviewing the study.
    Difference
    0.1%
    Check dated 2025-12-16T10:13:44.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    Revision indicator updated from v3.2.0 to v3.3.2 on the page.
    Difference
    0.1%
    Check dated 2025-11-24T21:32:59.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The notice about a lapse in government funding and operating status has been removed from the page; this does not affect the study details or how the page functions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T20:03:11.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    No significant changes detected between the old and new screenshots; the page content and structure remain focused on the study details.
    Difference
    0.4%
    Check dated 2025-11-03T13:51:43.000Z thumbnail image
  7. Check
    80 days ago
    Change Detected
    Summary
    Added a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.
    Difference
    3%
    Check dated 2025-10-06T04:35:49.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.